Desarrollo de hiperemia conjuntival tras el empleo de la combinación fija de latanoprost/timololrevisión sistemática y metaanálisis de ensayos clínicos publicados

  1. J.M. Vinuesa-Silva
  2. I. Vinuesa-Silva
  3. M.D. Pinazo-Durán
  4. J. Soto-Álvarez
  5. L. Delgado-Ortega
  6. S. Díaz-Cerezo
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2009

Volume: 84

Issue: 4

Pages: 199-207

Type: Article

DOI: 10.4321/S0365-66912009000400006 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Purpose: To asses the association of conjuntival hyperemia with the use of a fixed combination of latanoprost/timolol, through a systematic review and meta-analysis of clinical trials in patients with glaucoma. Methods: A systematic review of published clinical trials of latanoprost/timolol and other competitors was conducted in Medline, Embasse and Cochrane Controlled Clinical Trials Register, between 2000 and 2007. Statistical analysis included calculation of the odds ratio (OR) with its 95% confidence interval (CI) using the fixed effects model of Mantel-Haenszel and the random effects model of Der Simonian and Laird. To assess the heterogeneity between trials the Cochran Q test and the I² rate were calculated. The conjuntival hyperemia rates obtained were compared with the Chi-square test. Results: A total of 8 clinical trials comparing latanoprost/timolol fixed combination with different therapeutic options were found. As trial heterogeneity was moderate (Q: 14.64; df=7; p=0.041; I²= 52.2%) a random effects model was used. The final OR was 0.47 (CI 95%: 0.24-0.90); p = 0.024. The total conjuntival hyperemia incidence was 2.9% in the latanoprost/timolol group and 7.0% for the competitors (p< 0.0001). Conclusions: The use of a fixed combination of latanoprost/timolol is associated with a significant reduction (53%; CI 95%: 10%-76%) in the development of conjuntival hyperemia against the other compared options for the treatment of glaucoma.

Bibliographic References

  • El éxito en la lucha contra las enfermedades infecciosas y el envejecimiento de la población modifican el perfil epidemiológico mundial de la ceguera.
  • Kroese, M, Burton, H, Vardy, S, Rimmer, T, McCarter, D. (2002). Prevalence of primary open angle glaucoma in general ophthalmic practice in the United Kingdom. Br J Ophthalmol. 86. 978-980
  • Antón, A, Andrada, MT, Mujica, V, Calle, MA, Portela, J, Mayo, A. (2004). Prevalence of primary open-angle glaucoma in a Spanish population: the Segovia study. J Glaucoma. 13. 371-376
  • Friedman, DS, Jampel, HD, Muñoz, B, West, SK. (2006). The prevalence of open-angle glaucoma among blacks and whites 73 years and older: the Salisbury Eye Evaluation Glaucoma Study. Arch Ophthalmol. 124. 1625-1630
  • Glaucoma.
  • Kass, MA, Heuer, DK, Higginbotham, EJ, Johnson, CA, Keltner, JL, Miller, JP. (2002). The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 120. 701-713
  • (2003). Terminología y pautas en el glaucoma. 2. Dogma. Savona.
  • (2005). Primary Open-Angle Glaucoma: Preferred Practice Pattern. American Academy of Ophtalmology. San Francisco.
  • Friedman, DS, Quigley, HA, Gelb, L, Tan, J, Margolis, J, Shah, SN. (2007). Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 48. 5052-5057
  • Day, DG, Sharpe, ED, Atkinson, MJ, Stewart, JA, Stewart, WC. (2006). The clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patients. Eye. 20. 583-590
  • Joel, S, Schuman, MD. (2000). Antiglaucoma medication: a review of safety and tolerability issues related to their use. Clin Ther. 22. 167-208
  • Li, N, Chen, XM, Zhou, Y, Wei, ML, Yao, X. (2006). Travoprost compared with other prostaglandin analogues or timolol in patients with open-angle glaucoma or ocular hypertension: meta-analysis of randomized controlled trials. Clin Exp Ophthalmol. 34. 755-764
  • Feldman, RM. (2003). Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 19. 23-35
  • Jadad, AR, Moore, RA, Carroll, D, Jenkinson, C, Reynolds, DJ, Gavaghan, DJ. (1996). Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 17. 1-12
  • Higgins, JP, Thompson, SG, Deeks, JJ, Altman, DG. (2003). Measuring inconsistency in meta-analyses. BMJ. 327. 557-560
  • Mantel, J, Haenszel, W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 22. 719-748
  • Der Simonian, R, Laird, N. (1986). Meta-analysis in clinical trials. Control Clin Trials. 7. 177-188
  • Martín, JL, Martín-Sánchez, E, Torralba, E, Díaz, E, Lurueña-Segovia, S, Alonso, EJ. (2008). Investigación secundaria: revisión sistemática y metaanálisis. Semergen. 34. 11-16
  • Moher, D, Cook, DJ, Eastwood, S, Olkin, I, Rennie, D, Stroup, DF. (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: the QUORUM statement. Lancet. 354. 1896-1900
  • Delgado, M, Llorca, D, Doménech, JM. (2008). Estudios de cohortes: Metodología de la investigación en ciencias de la salud. 3. Signo. Barcelona.
  • Konstas, AG, Bányai, L, Blask, KD, Väth, J, Kozobolis, VP, Trüb, PR. (2004). Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther. 20. 375-382
  • Hamacher, T, Schinzel, M, Schölzel-Klatt, A, Neff, HM, Maier, H, Schlaffer, G. (2004). Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 88. 1295-1298
  • Konstas, AG, Nakos, E, Tersis, I, Lallos, NA, Leech, JN, Stewart, WC. (2002). A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol. Am J Ophthalmol. 133. 753-757
  • Cvenkel, B, Stewart, JA, Nelson, LA, Stewart, WC. (2008). Dorzolamide/timolol fixed combination versus latanoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension. Curr Eye Res. 33. 163-168
  • Stewart, WC, Stewart, JA, Day, DG, Sharpe, ED, Jenkins, JN. (2004). Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Eye. 18. 990-995
  • Stewart, WC, Stewart, JA, Day, D, Sharpe, ED. (2003). Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 81. 242-246
  • Konstas, AG, Kozobolis, VP, Lallos, N, Christodoulakis, E, Stewart, JA, Stewart, WC. (2004). Daytime diurnal curve comparison between the fixed combinations of latanoprost 0.005%/timolol maleate 0.5% and dorzolamide 2%/timolol maleate 0.5%. Eye. 18. 1264-1269
  • Konstas, AG, Boboridis, K, Tzetzi, D, Kallinderis, K, Jenkins, JN, Stewart, WC. (2005). Twenty-four-hour control with latanoprost-timolol-fixed combination therapy vs latanoprost therapy. Arch Ophthalmol. 123. 898-902
  • Shin, DH, Feldman, RM, Sheu, WP. (2004). Efficacy and safety of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure. Ophthalmology. 111. 276-282
  • Diestelhorst, M, Larsson, LI. (2004). A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 88. 199-203
  • Martinez, A, Sanchez, M. (2007). A comparison of the safety and intraocular pressure lowering of bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in patients with open-angle glaucoma. Curr Med Res Opin. 23. 1025-1032
  • Pfeiffer, N. (2002). A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe’s Arch Clin Exp Ophthalmol. 240. 893-899
  • Higginbotham, EJ, Feldman, R, Stiles, M, Dubiner, H. (2002). Latanoprost and timolol combination therapy vs monotherapy. Arch Ophthalmol. 120. 915-922
  • Olander, K, Zimmerman, TJ, Downes, N, Schoenfelder, J. (2004). Switching from latanoprost to fixed-combination latanoprost-timolol: A 21-day, randomized, double-masked, active-control study in patients with glaucoma and ocular hypertension. Clin Ther. 26. 1619-1629
  • Franks, WA, Renard, JP, Cunliffe, IA, Rojanapongpun, P. (2006). A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0.005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Clin Ther. 28. 332-339
  • García-Sánchez, J, Rouland, JF, Spiegel, D, Pajic, B, Cunliffe, I, Traverso, C. (2004). A comparison of the fixed combination of latanoprost and timolol with the unfixed combination of brimonidine and timolol in patients with elevated intraocular pressure: A six month, evaluator masked, multicentre study in Europe. Br J Ophthalmol. 88. 877-883
  • Diestelhorst, M, Larsson, LI. (2006). A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 113. 70-76
  • Martinez-de-la-Casa, JM, Castillo, A, Garcia-Feijoo, J, Mendez-Hernandez, C, Fernandez-Vidal, A, Garcia-Sanchez, J. (2004). Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin. 20. 1333-1339
  • Topouzis, F, Melamed, S, Danesh-Meyer, H, Wells, AP, Kozobolis, V, Wieland, H. (2007). A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 17. 183-190
  • Popoviç Suiç, S, Cerovski, B, Jukiç, T. (2008). The role of patient compliance in the management of glaucoma. Acta Med Croatica. 62. 57-59
  • Feldman, RM. (2003). Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension. J Ocul Pharmacol Ther. 19. 23-35
  • Holló, G. (2007). The side effects of the prostaglandin analogues. Expert Opin Drug Saf. 6. 45-52
Data source: Dialnet